Atea Pharmaceuticals, Inc. financial data

Symbol
AVIR on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2006% % 18%
Debt-to-equity 7.1% % -8.1%
Return On Equity -38% % -10%
Return On Assets -36% % -11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78,126,796 shares -7.5%
Common Stock, Shares, Outstanding 78,126,796 shares -7.5%
Entity Public Float $253,000,000 USD -11%
Common Stock, Value, Issued $78,000 USD -7.1%
Weighted Average Number of Shares Outstanding, Basic 79,052,154 shares -6.4%
Weighted Average Number of Shares Outstanding, Diluted 79,052,154 shares -6.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $125,877,000 USD -18%
General and Administrative Expense $39,102,000 USD -17%
Operating Income (Loss) $164,979,000 USD 18%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $146,194,000 USD 15%
Income Tax Expense (Benefit) $831,000 USD -21%
Net Income (Loss) Attributable to Parent $147,025,000 USD 16%
Earnings Per Share, Basic -1 USD/shares 14%
Earnings Per Share, Diluted -1 USD/shares 14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $77,344,000 USD -21%
Cash, Cash Equivalents, and Short-term Investments $329,309,000 USD -32%
Assets, Current $336,138,000 USD -31%
Property, Plant and Equipment, Net $561,000 USD -43%
Operating Lease, Right-of-Use Asset $789,000 USD -43%
Other Assets, Noncurrent $5,475,000 USD 225%
Assets $342,963,000 USD -30%
Accounts Payable, Current $3,515,000 USD -39%
Employee-related Liabilities, Current $4,888,000 USD 7.8%
Liabilities, Current $20,175,000 USD -20%
Accrued Income Taxes, Noncurrent $6,795,000 USD 9.6%
Operating Lease, Liability, Noncurrent $213,000 USD -80%
Liabilities $27,183,000 USD -16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $238,000 USD -63%
Retained Earnings (Accumulated Deficit) $477,702,000 USD -44%
Stockholders' Equity Attributable to Parent $315,780,000 USD -31%
Liabilities and Equity $342,963,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $30,563,000 USD 23%
Net Cash Provided by (Used in) Financing Activities $347,000 USD -331%
Net Cash Provided by (Used in) Investing Activities $85,608,000 USD 51%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 78,126,796 shares -7.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $54,698,000 USD 220%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $77,344,000 USD -21%
Deferred Tax Assets, Valuation Allowance $117,214,000 USD 58%
Deferred Tax Assets, Gross $117,214,000 USD 58%
Operating Lease, Liability $1,045,000 USD -43%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $147,428,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid $1,064,000 USD -44%
Property, Plant and Equipment, Gross $1,978,000 USD 0%
Operating Lease, Liability, Current $832,000 USD 5.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $855,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year One $855,000 USD 2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $19,000 USD -70%
Deferred Tax Assets, Operating Loss Carryforwards $19,514,000 USD 108%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $6,356,000 USD 10%
Additional Paid in Capital $793,166,000 USD 0.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $30,432,000 USD -39%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%